Novo Nordisk is advancing injectable and oral amycretin, one peptide that activates both GLP-1 and amylin receptors, into Phase 3 programs for obesity and type 2 diabetes.
Amycretin is a single molecule designed to act on both GLP-1 and amylin receptors, rather than combining two separate drugs the way CagriSema does. Novo Nordisk said it would move both subcutaneous and oral versions into Phase 3 weight-management trials, with the program slated to begin in early 2026, and it has also announced Phase 3 plans in type 2 diabetes.
The decision followed early-stage data in which weekly injectable amycretin produced up to about 22% weight loss over 36 weeks, and a daily oral form produced around 13% over 12 weeks. A Phase 2 diabetes study reported that weight loss had not plateaued at 36 weeks. Gastrointestinal effects were the most common side effects, in line with other incretin drugs.
Phase 3 results are still years away and detailed safety data remain limited. Amycretin is nonetheless seen as one of Novo's most important next-generation peptides as competition in obesity treatment intensifies.
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.